Krystal Total Stockholder Equity from 2010 to 2025
| KRYS Stock | USD 183.92 1.17 0.64% |
Total Stockholder Equity | First Reported 2016-12-31 | Previous Quarter 885.8 M | Current Value 946.4 M | Quarterly Volatility 294.5 M |
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 31.1 M, Interest Income of 31.1 M or Depreciation And Amortization of 7 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 4.5. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
Krystal | Total Stockholder Equity |
Latest Krystal Biotech's Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Krystal Biotech over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Krystal Biotech's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Krystal Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 280,890,500 | |
| Geometric Mean | 15,630,182 | |
| Coefficient Of Variation | 129.79 | |
| Mean Deviation | 305,158,500 | |
| Median | 113,226,000 | |
| Standard Deviation | 364,579,783 | |
| Sample Variance | 132918.4T | |
| Range | 993.4M | |
| R-Value | 0.90 | |
| Mean Square Error | 27657.6T | |
| R-Squared | 0.81 | |
| Slope | 68,740,138 | |
| Total Sum of Squares | 1993776.3T |
Krystal Total Stockholder Equity History
About Krystal Biotech Financial Statements
Krystal Biotech shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 946.4 M | 993.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.